Press Release

Monday, 01 October 2018

ARISE Trial inclusion completed – calculated sample size exceeded by participating hospitals

120 implantations was the calculated sample size for the ARISE study, which is trialing a novel type of graft – cell-free aortic homografts- for the replacement of aortic valves. 8 participating hospitals managed to include 138 patients according to schedule.

“This is a great success, which could only be accomplished by the extraordinary commitment within our ARISE study group”, emphasizes Prof. Haverich, the coordinator of the ARISE project. The next steps will be discussed during a Steering Committee Meeting, which will be held during the 2018 Annual Meeting of the European Association of Cardio-Thoracic Surgery (EACTS) in Milano. Publication of early data from the ARISE trial is envisaged for 2019.


Initial data of the outcome of cell-free homografts for pulmonary valve replacement will be presented at the 2018 EACTS during a Rapid Response – Congenital Session on Thursday 18th of October, 14:15-15:45, Room Titian.